Abstract
Recent advances in the synthetic biology field have enabled the development of new molecular biology techniques used to build specialized bacteriophages with new functionalities. Bacteriophages have been engineered towards a wide range of applications including pathogen control and detection, targeted drug delivery, or even assembly of new materials.
In this chapter, two strategies that have been successfully used to genetically engineer bacteriophage genomes are addressed: a yeast-based platform and bacteriophage recombineering of electroporated DNA.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Clark JR, March JB (2006) Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol 24:212–218
Kutter E, Vos DD, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69–86
Endersen L, O'Mahony J, Hill C, Ross RP, McAuliffe O, Coffey A (2014) Phage therapy in the food industry. Annu Rev Food Sci Technol 5:327–349
Jones JB, Jackson LE, Balogh B, Obradovic A, Iriarte FB, Momol MT (2007) Bacteriophages for plant disease control. Annu Rev Phytopathol 45:245–262
Monk AB, Rees CD, Barrow P, Hagens S, Harper DR (2010) Bacteriophage applications: where are we now? Lett Appl Microbiol 51:363–369
Schmelcher M, Loessner MJ (2014) Application of bacteriophages for detection of foodborne pathogens. Bacteriophage 4:e28137
Lu TK, Bowers J, Koeris MS (2013) Advancing bacteriophage-based microbial diagnostics with synthetic biology. Trends Biotechnol 31:325–327
Yacoby I, Bar H, Benhar I (2007) Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob Agents Chemother 51:2156–2163
Pande J, Szewczyk MM, Grover AK (2010) Phage display: concept, innovations, applications and future. Biotechnol Adv 28:849–858
Fehér T, Karcagi I, Blattner FR, Pósfai G (2012) Bacteriophage recombineering in the lytic state using the lambda red recombinases. Microb Biotechnol 5:466–476
Pires DP, Cleto S, Sillankorva S, Azeredo J, Lu TK (2016) Genetically engineered phages: a review of advances over the last decade. Microbiol Mol Biol Rev 80:523–543
Lu TKT, Koeris MS, Chevalier BS, Holder JW, McKenzie GJ, Brownell DR (2013) Recombinant phage and methods. Patents no. US20130122549 A1
Ando H, Lemire S, Pires DP, Lu TK (2015) Engineering modular viral scaffolds for targeted bacterial population editing. Cell Syst 1:187–196
Marinelli LJ, Piuri M, Swigoňová Z, Balachandran A, Oldfield LM, van Kessel JC, Hatfull GF (2008) BRED: a simple and powerful tool for constructing mutant and recombinant bacteriophage genomes. PLoS One 3:e3957
Marinelli L, Hatfull G, Piuri M (2012) Recombineering: A powerful tool for modification of bacteriophage genomes. Bacteriophage 2:5–14
Hanahan D (1983) Studies on transformation of Escherichia coli with plasmids. J Mol Biol 166:557–580
Murphy KC (2007) The λ Gam protein inhibits RecBCD binding to dsDNA ends. J Mol Biol 371:19–24
Court R, Cook N, Saikrishnan K, Wigley D (2007) The crystal structure of λ-Gam protein suggests a model for RecBCD inhibition. J Mol Biol 371:25–33
Datsenko KA, Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci 97:6640–6645
Xu K, Hua J, Roberts KJ, Figurski DH (2012) Production of recombineering substrates with standard-size PCR primers. FEMS Microbiol Lett 337:97–103
Swaminathan S, Ellis HM, Waters LS, Yu D, Lee EC, Court DL, Sharan SK (2001) Rapid engineering of bacterial artificial chromosomes using oligonucleotides. Genesis 29:14–21
Acknowledgements
This work was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the project PTDC/BBB-BSS/6471/2014, the strategic funding of UID/BIO/04469/2013 unit and COMPETE 2020 (POCI-01-0145-FEDER-006684), and under the scope of the Project RECI/BBB-EBI/0179/2012 (FCOMP-01-0124-FEDER-027462). This work was also supported by BioTecNorte operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020 – Programa Operacional Regional do Norte. Ana Rita Costa, Catarina Milho and Diana Priscila Pires acknowledge FCT for the grants SFRH/BPD/94648/2013, SFRH/BD/94434/2013 and SFRH/BPD/116187/2016, respectively.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Rita Costa, A., Milho, C., Azeredo, J., Pires, D.P. (2018). Synthetic Biology to Engineer Bacteriophage Genomes. In: Azeredo, J., Sillankorva, S. (eds) Bacteriophage Therapy. Methods in Molecular Biology, vol 1693. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7395-8_21
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7395-8_21
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7394-1
Online ISBN: 978-1-4939-7395-8
eBook Packages: Springer Protocols